ALAMEDA, Calif., July 21, 2026 Scribe Therapeutics is asking IPO buyers to finance a very early cardiometabolic CRISPR story, but it is not showing up alone. In its July 20 amended prospectus, Scribe laid out a 7.15 million share Nasdaq offering at $13 to $15 under the symbol SCTX, with estimated net proceeds from the IPO and a concurrent private placement of about $96.2 million at the midpoint. A Form 8-A filed on July 21 puts the trading mechanics in place. IPOGrid reads the real selling point as the financing package around the deal: Sanofi has agreed in the prospectus to buy about $7.5 million of stock in a concurrent private placement, and Eli Lilly has indicated interest in buying enough IPO shares to hold up to 10.9% of Scribe after the offering and placement.
That combination matters because biotech buyers still want visible validation before they fund platform stories. Scribe is offering a clinical-stage pitch centered on STX-1150, a first-in-human program in Australia for LDL-C reduction, with the prospectus saying initial safety, tolerability and LDL-C activity data are expected in the first half of 2027. Scribe is trying to sell the idea that its epigenetic silencing approach could deliver durable PCSK9 suppression without permanent DNA changes. That is a differentiated pitch for the public market, but it is still a pre-proof bet.
The broader financing map is more substantial than many small biotech launches. Besides the Sanofi placement and Lilly interest, Scribe said in a June 18 company release that it won more than $25 million from CIRM to advance the STX-1200 and STX-1400 cardiometabolic programs. The underwriter list in the S-1/A, Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities, also gives the deal more institutional shape than a typical single-asset biotech trying to force its way onto the calendar.
The use of proceeds is unusually explicit, and it tells investors what they are really funding. According to the prospectus, Scribe expects to spend roughly $30 million to $35 million on the ongoing Phase 1 trial for STX-1150, $15 million to $20 million on STX-1400, another $15 million to $20 million on STX-1200, and $20 million to $25 million on the rest of the pipeline, partnered programs and platform work. The filing also says the company believes the IPO proceeds, the Sanofi placement and existing cash should fund operations only into the first half of 2029, and that the company will still need substantial additional capital before any program reaches regulatory approval. Our interpretation is that investors are not buying a self-contained development runway here. They are financing the next set of value inflection points.
The income statement is where the caution flag goes up. In the audited 2025 figures, collaboration revenue rose to $51.2 million from $27.4 million and loss before income taxes narrowed to $23.6 million from $37.6 million. That looks healthier until you move into the current year. For the three months ended March 31, 2026, the same filing shows collaboration revenue falling 87% to $2.2 million from $17.1 million as Lilly milestone-related revenue did not recur and Sanofi workplan revenue dropped to zero. Net loss widened to $17.3 million from $3.4 million, helped lower by neither operating leverage nor recurring product revenue, but hurt in part by a $4.6 million unrealized loss tied to the fair value of a convertible note. Cash equivalents and investments stood at $49.6 million at March 31, 2026.
IPOGrid would frame that mix as both the appeal and the risk. The partner logos help, the bank group is credible, and the capital plan now includes private placement money and non-dilutive grant support. But Lilly's stated interest is still not a binding purchase commitment, and the company is still years away from the kind of clinical readout that can carry a cardiometabolic gene-editing valuation on fundamentals alone. Public investors are being asked to underwrite durability, not demonstrated human efficacy.
That makes Scribe worth watching this week. The deal has enough named support to command attention, and the July 21 8-A filing suggests it is moving through the last steps before trading. Still, the post-IPO argument will run through one Australian Phase 1 study, a collaboration-heavy revenue base, and management's ability to keep turning partner credibility into balance sheet time.